Current Problems in Cancer
Papers 887
1 page of 89 pages (887 results)
#1Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
Drug delivery to select therapeutic targets for precision oncology has always been a major challenge in oncology. Anti-body drug conjugates (ADC) and radiopharmaceuticals attempt to overcome the major limitations of chemotherapy or mono-clonal antibody therapy as they provide a highly specific means of attacking the vulnerability of the cancer cell. Currently there are over 100 clinical trials in various stages of development with these agents. Years of improved understanding of ADC technology a...
#1Roberto Carmagnani Pestana (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Jason Roszik (University of Texas MD Anderson Cancer Center)H-Index: 34
Last. Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
view all 7 authors...
Recent failure of phase 3 trials and paucity of druggable oncogenic drivers hamper developmental therapeutics in sarcomas. Antibody-based therapeutics, like antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR)-based therapeutics, have emerged as promising strategies for anticancer drug delivery. The efficacy of these novel therapies is highly dependent on expression of the antibody target. We used RNA sequencing data from Cancer Genome Atlas (TCGA) to analyze expression of target ...
#1Arielle Medford (Harvard University)H-Index: 5
#2Laura Spring (Harvard University)H-Index: 17
Last. Aditya Bardia (Harvard University)H-Index: 53
view all 4 authors...
The receptor-based classification of breast cancer predicts its optimal therapy. Hormone Receptor (HR) positive breast cancer is treated with endocrine therapy, and HER2+ disease is treated with HER2-targeted therapy. Triple negative breast cancer (TNBC), defined as tumors lacking HR and HER2, represents an aggressive subtype of breast cancer associated with poor prognosis. Development of targeted therapy for this subtype has been challenging since TNBC usually lacks targetable genomic alteratio...
#1Mai Lin (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Vincenzo Paolillo (University of Texas MD Anderson Cancer Center)H-Index: 8
Last. Gregory Ravizzini (University of Texas MD Anderson Cancer Center)H-Index: 6
view all 5 authors...
Abstract null null The concept of personalized medicine has been steadily growing for the past decades. Monoclonal antibodies (mAbs) are undoubtedly playing an important role in the transition away from conventional medical practice to a more tailored approach to deliver the best therapy with the highest safety margin to a specific patient. In certain instances, mAbs and antibody drug conjugates (ADCs) may represent the preferred therapeutic option for several types of cancers due to their high ...
#1Kalevi Kairemo (University of Texas MD Anderson Cancer Center)H-Index: 29
#2Jason Roszik (University of Texas MD Anderson Cancer Center)H-Index: 34
Last. Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 55
view all 7 authors...
Patients with osteoblastic metastases from high risk osteosarcoma continue to have a poor prognosis after progression from standard-of-care multi-agent chemotherapy. In a first-in-human dose escalation trial of bone targeted Radium 223 dichloride alpha-particle therapy in 18 patients with advanced osteosarcoma only 1 patient responded based on conventional Response Evaluation Criteria in Solid Tumors (RECIST). Na18F PET response Criteria in Solid Tumors(NAFCIST), based on Sodium fluoride-18 (Na1...
ABSTRACT null null To assess the recurrence of high-grade vaginal intraepithelial neoplasia (VAIN) after various treatments and to determine the factors affecting recurrence. A retrospective cohort study was conducted in patients with a histologic diagnosis of high-grade VAIN who underwent treatment between 1986 and 2013. Recurrence rates, life table analysis of recurrence-free intervals following treatment, and factors affecting recurrence were analyzed. Of the 104 included patients, the mean a...
#1Azim Jalali (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 2
#2Grace Gard (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 2
Last. Jeremy ShapiroH-Index: 29
view all 20 authors...
For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry was undertaken. The characteristics and outcomes of patients receiving TAS-102 were assess...
Besides traditional treatment strategies, including surgery, radiotherapy, and chemotherapy for lung cancer as the leading cause of cancer incidence and death, immunotherapy has also emerged as a new treatment strategy. The goal of immunotherapy is to stimulate the immune system responses against cancer, using various approaches such as therapeutic vaccines, monoclonal antibodies, immune checkpoint inhibitors, and T-cell therapy. Chimeric antigen receptor (CAR)-T cells, one of the most popular c...
#1Hamza Hashmi (MUSC: Medical University of South Carolina)H-Index: 1
#2Kimberly M. Green (MUSC: Medical University of South Carolina)H-Index: 1
Selinexor is a novel XPO1 inhibitor approved for patients with relapsed refractory multiple myeloma. When used as twice weekly dosing, selinexor is associated with significant toxicities, prohibiting its use in clinical practice. Newer combinations with other chemotherapeutic agents have evaluated less frequent and lower doses of Selinexor with aggressive supportive care. These novel combinations appear to have tolerable safety profiles while preserving drug efficacy, making Selinexor a reasonab...
#5Ki-Hyun Kim (SMC: Samsung Medical Center)H-Index: 33
Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a response-adapted strategy for elderly patients with newly diagnosed MM without high-risk features. Patients were administered single-agent lenalidomide for the first 21 days of two 28-day cycles. Patients with progressive disease recei...
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.